Literature DB >> 9184233

Rox, a novel bHLHZip protein expressed in quiescent cells that heterodimerizes with Max, binds a non-canonical E box and acts as a transcriptional repressor.

G Meroni1, A Reymond, M Alcalay, G Borsani, A Tanigami, R Tonlorenzi, C Lo Nigro, S Messali, M Zollo, D H Ledbetter, R Brent, A Ballabio, R Carrozzo.   

Abstract

Proteins of the Myc and Mad family are involved in transcriptional regulation and mediate cell differentiation and proliferation. These molecules share a basic-helix-loop-helix leucine zipper domain (bHLHZip) and bind DNA at the E box (CANNTG) consensus by forming heterodimers with Max. We report the isolation, characterization and mapping of a human gene and its mouse homolog encoding a new member of this family of proteins, named Rox. Through interaction mating and immunoprecipitation techniques, we demonstrate that Rox heterodimerizes with Max and weakly homodimerizes. Interestingly, bandshift assays demonstrate that the Rox-Max heterodimer shows a novel DNA binding specificity, having a higher affinity for the CACGCG site compared with the canonical E box CACGTG site. Transcriptional studies indicate that Rox represses transcription in both human HEK293 cells and yeast. We demonstrate that repression in yeast is through interaction between the N-terminus of the protein and the Sin3 co-repressor, as previously shown for the other Mad family members. ROX is highly expressed in quiescent fibroblasts and expression markedly decreases when cells enter the cell cycle. Moreover, ROX expression appears to be induced in U937 myeloid leukemia cells stimulated to differentiate with 12-O-tetradecanoylphorbol-13-acetate. The identification of a novel Max-interacting protein adds an important piece to the puzzle of Myc/Max/Mad coordinated action and function in normal and pathological situations. Furthermore, mapping of the human gene to chromosome 17p13.3 in a region that frequently undergoes loss of heterozygosity in a number of malignancies, together with the biochemical and expression features, suggest involvement of ROX in human neoplasia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9184233      PMCID: PMC1169897          DOI: 10.1093/emboj/16.10.2892

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  69 in total

1.  Correlation of two-hybrid affinity data with in vitro measurements.

Authors:  J Estojak; R Brent; E A Golemis
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

2.  Mxi2, a mitogen-activated protein kinase that recognizes and phosphorylates Max protein.

Authors:  A S Zervos; L Faccio; J P Gatto; J M Kyriakis; R Brent
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

3.  Detailed mapping and loss of heterozygosity analysis suggests a suppressor locus involved in sporadic breast cancer within a distal region of chromosome band 17p13.3.

Authors:  M Stack; D Jones; G White; D S Liscia; T Venesio; G Casey; D Crichton; J Varley; E Mitchell; J Heighway
Journal:  Hum Mol Genet       Date:  1995-11       Impact factor: 6.150

4.  Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.

Authors:  P J Hurlin; K P Foley; D E Ayer; R N Eisenman; D Hanahan; J M Arbeit
Journal:  Oncogene       Date:  1995-12-21       Impact factor: 9.867

Review 5.  The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.

Authors:  P J Hurlin; D E Ayer; C Grandori; R N Eisenman
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1994

6.  Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phenotype of human brain tumour cells.

Authors:  J Chen; T Willingham; L R Margraf; N Schreiber-Agus; R A DePinho; P D Nisen
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

7.  Discrimination between different E-box-binding proteins at an endogenous target gene of c-myc.

Authors:  L Desbarats; S Gaubatz; M Eilers
Journal:  Genes Dev       Date:  1996-02-15       Impact factor: 11.361

8.  Mutation of the MXI1 gene in prostate cancer.

Authors:  L R Eagle; X Yin; A R Brothman; B J Williams; N B Atkin; E V Prochownik
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

9.  p16 proteins from melanoma-prone families are deficient in binding to Cdk4.

Authors:  A Reymond; R Brent
Journal:  Oncogene       Date:  1995-09-21       Impact factor: 9.867

10.  Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.

Authors:  P J Hurlin; C Quéva; P J Koskinen; E Steingrímsson; D E Ayer; N G Copeland; N A Jenkins; R N Eisenman
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

View more
  44 in total

Review 1.  The Max network gone mad.

Authors:  T A Baudino; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

2.  Mad1 function is regulated through elements within the carboxy terminus.

Authors:  G Barrera-Hernandez; C M Cultraro; S Pianetti; S Segal
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

3.  MondoA, a novel basic helix-loop-helix-leucine zipper transcriptional activator that constitutes a positive branch of a max-like network.

Authors:  A N Billin; A L Eilers; K L Coulter; J S Logan; D E Ayer
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

4.  Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.

Authors:  D Xu; N Popov; M Hou; Q Wang; M Björkholm; A Gruber; A R Menkel; M Henriksson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

5.  Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells.

Authors:  Shala Dezfouli; Antony Bakke; Jie Huang; Anthony Wynshaw-Boris; Peter J Hurlin
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

Review 6.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 7.  Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis.

Authors:  Daniel Diolaiti; Lisa McFerrin; Patrick A Carroll; Robert N Eisenman
Journal:  Biochim Biophys Acta       Date:  2014-05-22

8.  Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis.

Authors:  C Quéva; G A McArthur; B M Iritani; R N Eisenman
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

9.  Deletion of Mnt leads to disrupted cell cycle control and tumorigenesis.

Authors:  Peter J Hurlin; Zi-Qiang Zhou; Kazuhito Toyo-oka; Sara Ota; William L Walker; Shinji Hirotsune; Anthony Wynshaw-Boris
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

10.  A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.

Authors:  Jason M Link; Sara Ota; Zi-Qiang Zhou; Colin J Daniel; Rosalie C Sears; Peter J Hurlin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.